ArticleFrontiers in endocrinology2017
Managing Transition in Patients Treated with Growth Hormone.
Article in Frontiers in endocrinology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Sucessful Transition in Rare Endocrine Diseases: Patient Experiences in a French Reference Centre.Clinical endocrinology · 2025Article
- [Management of transition growth hormone deficiency].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2024Article
- Policy for transitioning childhood-onset growth hormone deficiency from pediatric to adult endocrine care in Belgium.Frontiers in endocrinology · 2024Review
- Integrated Digital Health Solutions in the Management of Growth Disorders in Pediatric Patients Receiving Growth Hormone Therapy: A Retrospective Analysis.Frontiers in endocrinology · 2022Article
- An Adapted Model for Transition to Adult Care in Young Adults with Prader-Willi Syndrome.Journal of clinical medicine · 2021Article
- Connected health for growth hormone treatment research and clinical practice: learnings from different sources of real-world evidence (RWE)-large electronically collected datasets, surveillance studies and individual patients' cases.BMC medical informatics and decision making · 2021Article
- New Horizons in Short Children Born Small for Gestational Age.Frontiers in pediatrics · 2021Review
- Article
- Factors Driving Patient Preferences for Growth Hormone Deficiency (GHD) Injection Regimen and Injection Device Features: A Discrete Choice Experiment.Patient preference and adherence · 2020Article
- Shared Decision-Making in Growth Hormone Therapy-Implications for Patient Care.Frontiers in endocrinology · 2018Review
- Optimizing Patient Management and Adherence for Children Receiving Growth Hormone.Frontiers in endocrinology · 2017Article
- Short Stature Diagnosis and Referral.Frontiers in endocrinology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Growth hormone (GH) promotes growth in children, but is also essential for bone strength, body composition, metabolic factors, such as lipid profile, and maintenance of quality of life. The Merck KGaA (Germany) funded "360° GH in Europe" meeting, held in Lisbon, Portugal, in June 2016, comprised three sessions entitled "
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.